Poly(ε-caprolactone), Eudragit® RS 100 and poly(ε-caprolactone)/Eudragit® RS 100 blend submicron particles for the sustained release of the antiretroviral efavirenz.

[1]  G. Attizzani,et al.  Local delivery of sirolimus nanoparticles for the treatment of in‐stent restenosis , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[2]  A. Concheiro,et al.  Hot melt poly-ε-caprolactone/poloxamine implantable matrices for sustained delivery of ciprofloxacin. , 2012, Acta biomaterialia.

[3]  B. Bastakoti,et al.  Incorporation and release behavior of amitriptylene in core-shell-corona type triblock copolymer micelles. , 2011, Colloids and surfaces. B, Biointerfaces.

[4]  D. Chiappetta,et al.  Efavirenz is a substrate and in turn modulates the expression of the efflux transporter ABCG2/BCRP in the gastrointestinal tract of the rat. , 2011, Biochemical pharmacology.

[5]  G. Abraham,et al.  Fast and efficient synthesis of high molecular weight poly(epsilon-caprolactone) diols by microwave-assisted polymer synthesis , 2011 .

[6]  Kurt E. Geckeler,et al.  Polymer nanoparticles: Preparation techniques and size-control parameters , 2011 .

[7]  M. Gill,et al.  Impact of current antiretroviral therapies on neuroAIDS , 2011, Expert review of anti-infective therapy.

[8]  S. Uzzau,et al.  Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies , 2011, Nanoscale research letters.

[9]  A. Epstein,et al.  Loss of Neuronal Integrity during Progressive HIV-1 Infection of Humanized Mice , 2011, The Journal of Neuroscience.

[10]  D. Chiappetta,et al.  Oral pharmacokinetics of the anti-HIV efavirenz encapsulated within polymeric micelles. , 2011, Biomaterials.

[11]  S. Davaran,et al.  Preparation and physicochemical characterization of naproxen-PLGA nanoparticles. , 2010, Colloids and surfaces. B, Biointerfaces.

[12]  A. Concheiro,et al.  N-alkylation of poloxamines modulates micellar assembly and encapsulation and release of the antiretroviral efavirenz. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[13]  D. Chiappetta,et al.  Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles. , 2010, Colloids and surfaces. B, Biointerfaces.

[14]  R. Duval,et al.  Cytotoxicity assessment of heparin nanoparticles in NR8383 macrophages. , 2010, International journal of pharmaceutics.

[15]  M. Harris-White,et al.  Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction , 2010, Immunologic research.

[16]  R. Yokel,et al.  Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses , 2010, Journal of drug targeting.

[17]  W. Frey,et al.  Intranasal delivery to the central nervous system: mechanisms and experimental considerations. , 2010, Journal of pharmaceutical sciences.

[18]  X. Wu,et al.  Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. , 2010, Advanced drug delivery reviews.

[19]  P. Sinko,et al.  Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs. , 2010, Advanced drug delivery reviews.

[20]  D. Chiappetta,et al.  Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected]. , 2010, Nanomedicine.

[21]  Arvind K. Jain,et al.  Evaluation of Mucoadhesive PLGA Microparticles for Nasal Immunization , 2010, The AAPS Journal.

[22]  N. Shaik,et al.  Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies. , 2009, Journal of Pharmacy and Science.

[23]  Lisbeth Illum,et al.  Nanoparticles for direct nose-to-brain delivery of drugs. , 2009, International journal of pharmaceutics.

[24]  D. Chiappetta,et al.  Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[25]  A. Trapani,et al.  The use of Eudragit RS 100/cyclodextrin nanoparticles for the transmucosal administration of glutathione. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[26]  H. Gendelman,et al.  NanoART, neuroAIDS and CNS drug delivery. , 2009, Nanomedicine.

[27]  D. Hutmacher,et al.  The return of a forgotten polymer : Polycaprolactone in the 21st century , 2009 .

[28]  E. Masliah,et al.  Molecular Pathology of Neuro-AIDS (CNS-HIV) , 2009, International journal of molecular sciences.

[29]  N. Shaik,et al.  Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors. , 2008, Journal of pharmaceutical sciences.

[30]  R. Bendayan,et al.  Regulation of ABC membrane transporters in glial cells: Relevance to the pharmacotherapy of brain HIV‐1 infection , 2008, Glia.

[31]  A. Van Rie,et al.  Impact of the HIV/AIDS Epidemic on the Neurodevelopment of Preschool-Aged Children in Kinshasa, Democratic Republic of the Congo , 2008, Pediatrics.

[32]  Antonello A Barresi,et al.  Strategies to control the particle size distribution of poly-epsilon-caprolactone nanoparticles for pharmaceutical applications. , 2008, Journal of colloid and interface science.

[33]  Ming Zhao,et al.  Synthesis, nano-scale assembly, and in vivo anti-thrombotic activity of novel short peptides containing L-Arg and L-Asp or L-Glu. , 2008, Bioorganic & medicinal chemistry.

[34]  S. Guterres,et al.  Incorporation in polymeric nanocapsules improves the antioxidant effect of melatonin against lipid peroxidation in mice brain and liver. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[35]  S. Echevarría,et al.  Glucoproteína P e infección por el virus de la inmunodeficiencia humana , 2008 .

[36]  R. Pomerantz,et al.  Hide-and-seek: the challenge of viral persistence in HIV-1 infection. , 2008, Annual review of medicine.

[37]  Jagdish Singh,et al.  Poly (lactide-co-glycolide)-Polymethacrylate Nanoparticles for Intramuscular Delivery of Plasmid Encoding Interleukin-10 to Prevent Autoimmune Diabetes in Mice , 2008, Pharmaceutical Research.

[38]  D. Chiappetta,et al.  Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[39]  W. Tyor,et al.  Highly active antiretroviral therapy of cognitive dysfunction and neuronal abnormalities in SCID mice with HIV encephalitis , 2007, Experimental Neurology.

[40]  C. Higgins,et al.  Multiple molecular mechanisms for multidrug resistance transporters , 2007, Nature.

[41]  Fan Wu,et al.  Preparation of hemoglobin-loaded nano-sized particles with porous structure as oxygen carriers. , 2007, Biomaterials.

[42]  L. Hanson,et al.  Strategies for Intranasal Delivery of Therapeutics for the Prevention and Treatment of NeuroAIDS , 2007, Journal of Neuroimmune Pharmacology.

[43]  M. Delaney.  History of HAART – the true story of how effective multi-drug therapy was developed for treatment of HIV disease , 2006, Retrovirology.

[44]  R. Gurny,et al.  Intraocular implants for extended drug delivery: therapeutic applications. , 2006, Advanced drug delivery reviews.

[45]  Mansoor M. Amiji,et al.  Intracellular Delivery of Saquinavir in Biodegradable Polymeric Nanoparticles for HIV/AIDS , 2006, Pharmaceutical Research.

[46]  N. Sacktor,et al.  Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system , 2006, Current opinion in neurology.

[47]  Y. Tabata,et al.  Aminated gelatin microspheres as a nasal delivery system for peptide drugs: evaluation of in vitro release and in vivo insulin absorption in rats. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[48]  Ho Seok Lee,et al.  The effect of type of organic phase solvents on the particle size of poly(d,l-lactide-co-glycolide) nanoparticles , 2006 .

[49]  Avraham Levi,et al.  PEO-PPO-PEO-based poly(ether ester urethane)s as degradable reverse thermo-responsive multiblock copolymers. , 2006, Biomaterials.

[50]  Cunxian Song,et al.  The in vivo degradation, absorption and excretion of PCL-based implant. , 2006, Biomaterials.

[51]  F. Romanelli,et al.  Use of virostatics as a means of targeting human immunodeficiency virus infection. , 2006, Current pharmaceutical design.

[52]  P. Sinko,et al.  P-Glycoprotein and Mutlidrug Resistance-Associated Proteins Limit the Brain Uptake of Saquinavir in Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.

[53]  L. Illum.  Is nose‐to‐brain transport of drugs in man a reality? , 2004, The Journal of pharmacy and pharmacology.

[54]  D. Cohn,et al.  Poly(ethylene glycol)-poly(epsilon-caprolactone) block oligomers as injectable materials , 2003 .

[55]  J. Benoit,et al.  Effect of the type of hydrophobic polymers on the size of nanoparticles obtained by emulsification–solvent evaporation , 2003 .

[56]  Michael J. Rathbone,et al.  Development of an injection molded poly(ε-caprolactone) intravaginal insert for the delivery of progesterone to cattle , 2002 .

[57]  Mansoor M. Amiji,et al.  BIODEGRADABLE POLY (E-CAPROLACTONE) NANOPARTICLES FOR TUMOR-TARGETED DELIVERY OF TAMOXIFEN , 2002 .

[58]  V. Babak,et al.  Low Molecular Weight Heparin-Loaded Polymeric Nanoparticles: Formulation, Characterization, and Release Characteristics , 2002, Drug development and industrial pharmacy.

[59]  N. Kumar,et al.  Biodegradable block copolymers. , 2001, Advanced drug delivery reviews.

[60]  P. Costa,et al.  Modeling and comparison of dissolution profiles. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[61]  A. Rzhetsky,et al.  The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Genome research.

[62]  L. Andrews,et al.  Progress in HIV therapeutics and the challenges of adherence to antiretroviral therapy. , 2000, Infectious disease clinics of North America.

[63]  E. Gotuzzo,et al.  Bartonellosis. New and old. , 2000, Infectious disease clinics of North America.

[64]  P. Sinko,et al.  Involvement of multiple transporters in the oral absorption of nucleoside analogues. , 1999, Advanced drug delivery reviews.

[65]  B. Aungst,et al.  P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. , 1999, Advanced drug delivery reviews.

[66]  Joseph Kost,et al.  Handbook of Biodegradable Polymers , 1998 .

[67]  J Chen,et al.  [The mechanism of degradation for the absorbable biomaterials poly(epsilon-caprolactone) in vitro and in vivo]. , 1997, Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi.

[68]  A. Rolland,et al.  Blood clearance and organ distribution of intravenously administered polymethacrylic nanoparticles in mice. , 1989, Journal of pharmaceutical sciences.

[69]  Nicholas A. Peppas,et al.  A simple equation for description of solute release II. Fickian and anomalous release from swellable devices , 1987 .

[70]  Nicholas A. Peppas,et al.  A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs , 1987 .